pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia
BeiGene
BeiGene is a pharma organization headquartered in Camana Bay, KY. Primary therapeutic focus areas include Advanced or metastatic solid tumors, Waldenström's Macroglobulinemia, Covid19, Ovarian Cancer, Carcinoma, Hepatoce
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US HQ
2010 Founded
2,047 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
- Founded
- 2010
- Employees
- 2,047
- Programs
- 14
- Drugs
- 19
- Patents
- 25
OBINUTUZUMAB, Zanubrutinib
Phase 2 · small molecule · Relapsed/Refractory Follicular Lymphoma
OBINUTUZUMAB, Zanubrutinib for Relapsed/Refractory Follicular Lymphoma is a Phase 2 program (small_molecule) at BeiGene with 1 ClinicalTrials.gov record(s).
Internal code BGB-3111-212
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BeiGene
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Relapsed/Refractory Follicular Lymphoma
- Status
- active
- Trials
- 1